An analysis of intravenous immunoglobin site of care: Home versus outpatient hospital

American Journal of Pharmacy Benefits

Volumn 6, Issue 2, 2014, Pages

  Luthra, Rakesh ^a   Quimbo, Ralph ^a   Iyer, Ravi ^b   Luo, Michelle ^b  

^a HEALTHCORE INC   (United States)

^b BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; HEALTH CARE; HEALTH CARE COST; HEALTH INSURANCE; HOME CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OBSERVATIONAL STUDY; OUTPATIENT DEPARTMENT; PRESCRIPTION; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 84898797699     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Notarangelo L, Casanova JL, Conley ME, et al. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee Meeting in Budapest, 2005. J Allergy Clin Immunol. 2006;117(4):883-896.
2. Cunningham-Rundles C, Ponda PP. Molecular defects. Nat Rev Immunol. 2005;5(11):880-892.
3. Primary immunodeficiency. National Institute of Child Health and Human Development website. http://www.nichd.nih.gov/publications/pubs/Pages/primary_immuno.aspx. Updated April 7, 2008.
4. Epstein MM, Gruskay F. Selective deficiency in pneumococcal antibody response in children with recurrent infections. Ann Allergy Asthma Immunol. 1995;75(2):125-131.
5. Sorensen RU, Moore C. Immunology in the pediatrician's office. Pediatr Clin North Am. 1994;41(4):691-714.
6. Scientists identify genetic cause of previously undefined primary immune deficiency disease. National Institute of Allergy and Infectious Diseases website. http://www.niaid.nih.gov/news/newsreleases/2009/pages/dock8.aspx. Updated September 24, 2009. Accessed February 9, 2012.
7. Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007;27(5):497-502.
8. Modell V, Gee B, Lewis DB, et al. Global study of primary immunodeficiency diseases (PI)--diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res. 2011;51(1):61-70.
9. Patient and Family Handbook for Primary Immunodeficiency Diseases, 5th ed. USA: Towson, MD: Immune Deficiency Foundation; 2013.
10. Joshi AY, Iyer VN, Hagan JB, St Sauver JL, Boyce TG. Incidence and temporal trends of primary immunodeficiency: a population-based cohort study. Mayo Clin Proc. 2009;84(1):16-22.
11. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117(4 suppl):S525-S553.
12. Sacher RA. Intravenous immunoglobulin consensus statement. J Allergy Clin Immunol. 2001;108(4 suppl):S139-S146.
13. Gammagard S/D Immune Globulin Intravenous (Human) IgA less than 2.2 [prescribing information]. Baxter Healthcare Corporation. Revised December 2010. Deerfield, Ill.
14. Bonilla FA, Bernstein IL, Khan DA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol. 2005;94(5 suppl):S1-S63.
15. Eijkhout HW, Der Meer JW, Kallenberg CG, et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia: a randomized, double-blind, multicenter crossover trial. Ann Intern Med. 2001;135(3):165-174.
16. Roifman CM, Gelfand EW. Replacement therapy with high dose intravenous gamma-globulin improves chronic sinopulmonary disease in patients with hypogammaglobulinemia. Pediatr Infect Dis J. 1988;7(5 suppl):S92-S96.
17. Schiff RI, Rudd C. Alterations in the half-life and clearance of IgG during therapy with intravenous gamma-globulin in 16 patients with severe primary humoral immunodeficiency. J Clin Immunol. 1986;6(3):256-264.
18. Kirmse J. The nurse's role in administration of intravenous immunoglobulin therapy. Home Healthc Nurse. 2009;27(2):104-111.
19. Birnbaum HG, Tang M. The Home Infusion Therapy/Relative Benefit Index: summary of an analysis using insurance claims data. Med Care. 1998;36(5): 757-765.
20. Hooker L, Kohler J. Safety, efficacy, and acceptability of home intravenous therapy administered by parents of pediatric oncology patients. Med Pediatr Oncol. 1999;32(6):421-426.
21. Watters C. The benefits of providing chemotherapy at home. Prof Nurse. 1997;12(5):367-370.
22. Williams DN. Home intravenous anti-infective therapy (HIVAT): do the benefits outweigh the risks? Drug Saf. 1996;14(1):1-7.
23. Walsh's outlier test. Fundamentals of Statistics website. http://www.statistics4u.com/fundstat_eng/ee_walsh_outliertest.html. Accessed December 21, 2012.
24. Bach JP, Riedel O, Klotsche J, Spottke A, Dodel R, Wittchen HU. Impact of complications and comorbidities on treatment costs and health-related quality of life of patients with Parkinson's disease. J Neurol Sci. 2012;314(1-2):41-47.
25. McLaughlin TP, Khandker RK, Kruzikas DT, Tummala R. Overlap of anxiety and depression in a managed care population: prevalence and association with resource utilization. J Clin Psychiatry. 2006;67(8):1187-1193.
26. Walid MS, Robinson JS. Economic impact of comorbidities in spine surgery. J Neurosurg Spine. 2011;14(3):318-321.
27. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
28. American Pharmacists Association/APhA. (2003). Medication Compliance- Adherence-Persistence (CAP) Digest. Washington, DC: American Pharmacists Association and Pfizer Pharmaceuticals; 2012.
29. Balkrishnan R, Rajagopalan R, Camacho FT, Huston SA, Murray FT, Anderson RT. Predictors of medication adherence and associated healthcare costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther. 2003;25(11):2958-2971.
30. Dragomir A, Cote R, Roy L, Blais L, Lalonde L, Berard A, Perreault S. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care. 2010;48(5):418-425.
31. Gwadry-Sridhar FH, Manias E, Zhang Y, et al. A framework for planning and critiquing medication compliance and persistence research using prospective study designs. Clin Ther. 2009;31(2):421-435.
32. Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care. 2004;27(9):2149-2153.
33. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6): 521-530.
34. Liu Z, Albon E, Hyde C.The effectiveness and ciost effectiveness of immunoglobulin replacement therapy for primary immunodeficiency and chronic lymphocytic leukaemia: a systematic review and economic evaluation. Birmingham, AL: Department of Public Health and Epidemiology, University of Birmingham; 2005.
35. Vergnenegre A, Decroisette C, Vincent F, et al. [Economic analysis of home based versus hospital outpatient chemotherapy in stage IV non small cell lung cancer]. Rev Mal Respir. 2006;23(3, pt 1):255-263.
36. Joo EH, Rha SY, Ahn JB, Kang HY. Economic and patient-reported outcomes of outpatient home-based versus inpatient hospital-based chemotherapy for patients with colorectal cancer. Support Care Cancer. 2011;19(7):971-978.
37. Lucas M, Hugh-Jones K, Welby A, Misbah S, Spaeth P, Chapel H. Immunomodulatory therapy to achieve maximum efficacy: doses, monitoring, compliance, and self-infusion at home. J Clin Immunol. 2010;30(suppl 1):S84-S89.
38. Nicolay U, Haag S, Eichmann F, Herget S, Spruck D, Gardulf A. Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy. Qual Life Res. 2005;14(7): 1683-1691. - See more at: http://www.ajmc.com/publications/ajpb/2014/ajpb_marapr2014/an-analysis-of-intravenous-immunoglobin-site-of-care-home-versus-outpatient-hospital/5#sthash.BEbGxwR8.dpuf